Infants and children aged <2 years are strongly recommended to receive MenACWY vaccine in a 1-, 2- or 3-dose schedule, depending on the vaccine brand and the child’s age when they start the vaccine course. See Table. Recommendations for immunisation of infants and children aged <2 years using meningococcal ACWY vaccines, by age and vaccine brand for more details.

Infants can receive their 1st dose of MenACWY vaccine as early as 6 weeks of age. Menveo is registered for use in people aged ≥2 months. However, infants can receive their 1st dose of either of these vaccines as early as 6 weeks of age.

There are 3 MenACWY vaccines: Menactra, Menveo and Nimenrix. In children <2 years of age, there is no preference for use of one vaccine brand over another when following the brand-specific dosing schedule.

For infants aged <6 months who are travelling to areas where meningococcal A disease is common and who are receiving Menveo, a 4-dose schedule (given as a 3+1 schedule) should be considered for optimal protection against serogroup A. Three primary doses should be given with an interval of 8 weeks between doses, followed by a 4th dose at 12 months age.

Table. Recommendations for immunisation of infants and children aged <2 years using meningococcal ACWY vaccines, by age and vaccine brand

Medical conditions are specified in List. Specified medical conditions associated with increased risk of invasive meningococcal disease.

Age at start of vaccine course

MenACWY vaccine brand

Dose requirements for healthy people (without any medical conditions associated with increased risk of invasive meningococcal disease)

6 weeks to 5 months

Menveoa

Nimenrix

3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age)

6–8 months

Menveo

Nimenrix

2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later)

9–11 months

Menveo

Nimenrix

Menactra

2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later)

12–23 months

Menveo

2 doses (8 weeks between doses)

Nimenrix

1 dose

Menactra

2 doses (8 weeks between doses)

a. For optimal protection against serogroup A, an extra primary dose (ie a 3+1 schedule) of Menveo should be considered for infants aged <6 months, if travelling to areas where meningococcal A disease is common

Page history

Last updated: 
8 June 2018
Last reviewed: 
8 June 2018